key: cord-0881378-yg1dpain
authors: Mitchell, Ruth A.; King, James A. J.; Goldschlager, Tony; Wang, Yi Yuen
title: Impact of COVID‐19 on pituitary surgery
date: 2020-05-05
journal: ANZ J Surg
DOI: 10.1111/ans.15959
sha: 81486930598616043b7dac4ae5b9f272ad3a3f2c
doc_id: 881378
cord_uid: yg1dpain

nan

Throughout the world, there has been a strong recommendation to avoid trans-sphenoidal approaches for pituitary tumours. International specialist societies including our own Neurosurgery Society of Australasia have recommended 'serious consideration be given to avoiding a trans-sphenoidal approach due to extremely high viral transmission risk'. Fortunately, most pituitary tumours are slowgrowing benign lesions and close monitoring with regular radiological imaging and visual assessment remains a viable option for pituitary tumour patients.

A small proportion of pituitary tumours however will require surgical intervention acutely due to deteriorating visual acuity or visual fields across serial ophthalmological assessment, as well as pituitary apoplexy causing rapid loss of vision including blindness. In these situations, consideration must be given to the surgical alternative of an open craniotomy to allow access to the pituitary tumour and decompression of the optic apparatus. Whilst the risk profile of a craniotomy is higher compared to that of a trans-sphenoidal approach, 4 the public health risk to the entire surgical team (doctors, nurses and technicians) and subsequently their contacts in proceeding with an aerosol-generating trans-sphenoidal surgery far outweighs the individual risk to the patient.

An even smaller proportion of pituitary tumours may present with acute medical manifestations due to hormonal imbalances. Where possible, these should be managed medically under close supervision of an endocrinologist. Fulminant Cushing's disease is the one rare situation whereby a short period of medical management might fail, and in this situation careful discussion with the treating medical and surgical team must be undertaken in the context of the COVID-19 pandemic to guide surgical approach.

We are not suggesting that a craniotomy for a pituitary tumour is superior to a trans-sphenoidal approach. Indeed, our extensive experience across three high-volume pituitary centres confirms that visual and endocrine outcomes are optimized via the transsphenoidal approach. Likewise, we are not suggesting that all pituitary tumours undergo a craniotomy; however, in the current climate of COVID-19, we would strongly recommend a protocol of close monitoring of pituitary tumour patients and proceeding with a craniotomy for those patients who warrant urgent surgical intervention.

Finally, it is important to consider the psychology of the patient throughout this situation. Many pituitary tumour patients are well informed having been down a long journey to diagnosis, and to be told their surgical treatment will be delayed (indefinitely) or be considered for a craniotomy may impact on their mental well-being. Having held several discussions with our current pituitary patients, it is important to reassure them of the safety of the current approach, to empathize with their situation and to be in regular contact with them during this period. Whilst we are acting for the good of the overall community, it can be a long and lonely path to walk for the individual patient affected by these decisions.

Integrated infection control strategy to minimize nosocomial infection of coronavirus disease 2019 among ENT healthcare workers

Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review

SARS-CoV-2 viral load in upper respiratory specimens of infected patients

Outcomes of surgically treated giant pituitary tumours. Can